An interventional study of Bismuth and Bismuth quadruple therapy in Helicobatcer Pylori and First-Line Eradication, sponsored by Chih-An Shih, MD. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Chih-An Shih, MD · Not applicable, Interventional, and Treatment
Most international treatment guidelines currently recommend a 14-day bismuth quadruple therapy as the first-line treatment for Helicobacter pylori infection, especially in areas with high clarithromycin resistance. While this therapy boasts good eradication rates, its administration is complex and has a high incidence of adverse reactions. However, tetracycline is one of the most effective anti-Helicobacter pylori antibiotics, with a resistance rate of less than 3%. This study prospectively evaluates the efficacy and safety of a 14-day triple therapy (high-dose tetracycline combined with bismuth and PPI) versus a 14-day bismuth quadruple therapy as first-line eradication therapy. This novel single-antibiotic therapy has the potential to become a new standard of care for Helicobacter pylori eradication.
adult patients (aged ≥18 years) who underwent esophagogastroduodenoscopy for the evaluation of gastrointestinal symptoms at Antai Tian-Sheng Memorial Hospital. Eligible individuals were invited to participate in an H. pylori screening program. Those who met either of the following criteria were considered for enrollment: (1) positive results from both the rapid urease test and histology, or (2) a positive culture result.
Exclusion Criteria:
(1) previous H. pylori eradication therapy, (2) a history of gastrectomy, (3) allergy to any of the eradication medications used in this study, (4) antibiotic use within 4 weeks before treatment, (5) the absence of post-treatment assessment for H. pylori eradication.
Bismuth、Tetracycline、Rabeprazole
Drug: Bismuth · Drug: Bismuth quadruple therapy
Bismuth、Tetracycline、Rabeprazol、Metronidazole
Drug: Bismuth · Drug: Bismuth quadruple therapy
14-day Bismuth-Tetracycline-Rabeprazole Triple
Also known as: Tetracycline, Rabeprazole
Bismuth quadruple therapy, combining Rabeprazole, Tetracycline, Bismuth, and Metronidazole
Also known as: Rabeprazole, Tetracycline, Metronidazole
eradication rate
Follow-up at week 2 will assess treatment adherence and adverse events. H. pylori status will be evaluated at week 6 using the C13-urea breath test. Eradication and adverse event rates will be compared between groups using the chi-square test.
Time frame: 6 weeks
Plan to share: No
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.